General MedicationsORALGeneric
VANSIL
OXAMNIQUINE
Standard Dose
250MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview VANSIL is listed in Drugs@FDA under application 018069 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient OXAMNIQUINE Form and strength CAPSULE;ORAL - 250MG Sponsor PFIZER Submission history Latest submission status date: 1992-02-24 00:00:00.
Structured Monograph
Clinical summary
Approval overview VANSIL is listed in Drugs@FDA under application 018069 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient OXAMNIQUINE Form and strength CAPSULE;ORAL - 250MG Sponsor PFIZER Submission history Latest submission status date: 1992-02-24 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.